ArticleAmerican journal of cancer research2016
miR-186 inhibits cell proliferation of prostate cancer by targeting GOLPH3.
Article in American journal of cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 42 citations in OpenAlex.
- Protosappanin B enhances the chemosensitivity of 5-fluorouracil in colon adenocarcinoma by regulating the LINC00612/microRNA-590-3p/Golgi phosphoprotein 3 axis.Discover oncology · 2024Article
- Mechanisms of Long Non-Coding RNA in Breast Cancer.International journal of molecular sciences · 2023Review
- MicroRNA-186 suppresses cell proliferation and metastasis in bladder cancer.African health sciences · 2022Article
- MiR-186-3p attenuates tumorigenesis of cervical cancer by targeting IGF1.World journal of surgical oncology · 2021Article
- miR-186 Inhibits Liver Cancer Stem Cells ExpansionFrontiers in oncology · 2021Article
- Advancement and properties of circular RNAs in prostate cancer: An emerging and compelling frontier for discovering.International journal of biological sciences · 2021Review
- Ameliorative effects of miR-186 on cisplatin-triggered acute kidney injury via targeting ZEB1.American journal of translational research · 2021Article
- Radiation Can Regulate the Expression of miRNAs Associated with Osteogenesis and Oxidation in Exosomes from Peripheral Blood Plasma.Oxidative medicine and cellular longevity · 2021Article
- The Dual Role of miR-186 in Cancers: Oncomir Battling With Tumor Suppressor miRNA.Frontiers in oncology · 2020Review
- Recurrence-Associated Multi-RNA Signature to Predict Disease-Free Survival for Ovarian Cancer Patients.BioMed research international · 2020Article
- Deep RNA-Seq reveals miRNome differences in mammary tissue of lactating Holstein and Montbéliarde cows.BMC genomics · 2019Article
- MicroRNA Dysregulation in Cutaneous Squamous Cell Carcinoma.International journal of molecular sciences · 2019Review
- MicroRNA-186 targets SKP2 to induce p27The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2019Article
- LncRNA SNHG16 Promotes Hepatocellular Carcinoma Proliferation, Migration and Invasion by Regulating miR-186 Expression.Journal of Cancer · 2019Article
- PVT1 Promotes Cancer Progression via MicroRNAs.Frontiers in oncology · 2019Review
- Knockdown of long non-coding RNACancer biology & medicine · 2018Article
- Micro-RNA-186-5p inhibition attenuates proliferation, anchorage independent growth and invasion in metastatic prostate cancer cells.BMC cancer · 2018Article
- Long Noncoding RNA ANRIL Promotes Cervical Cancer Development by Acting as a Sponge of miR-186.Oncology research · 2018Article
- miR‑186, a serum microRNA, induces endothelial cell apoptosis by targeting SMAD6 in Kawasaki disease.International journal of molecular medicine · 2018Article
- MicroRNA-186 Suppresses Cell Proliferation and Metastasis Through Targeting Sentrin-Specific Protease 1 in Renal Cell Carcinoma.Oncology research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is one of the leading causes of cancer deaths among men, many miRNAs have been demonstrated to play critical role in the progression of prostate cancer, miR-186 suppresses the progression of many tumors, such as bladder cancer and glioma. Previous study shows miR-186 is downregulated in prostate cancer tissues, and is a good prognosis for prostate cancer patients. In this study, we found miR-186 was downregulated in prostate cancer cells and tissues, overexpression of miR-186 inhibited cell proliferation and tumorigenesis in vitro determined by MTT assay, colony formation assay and soft agar growth assay, whereas knockdown of miR-186 reduced these effects. Cell cycle analysis found miR-186 overexpression arrested cell cycle in G0/G1 phase, and reduced p21 and p27 levels, and enhanced Cyclin D1 and the phosphorylation of Rb levels, suggesting miR-186 blocked G1/S transition. A novel oncogene Golgi phhosphoprotein 3 (GOLPH3) was the target of miR-186, miR-186 bound to the 3'UTR of GOLPH3. Moreover, miR-186 was negatively correlated with GOLPH3 in prostate cancer tissues. In conclusion, our study suggested miR-186 inhibited cell proliferation through targeting oncogene GOLPH3.
Indexed as
Identifiers
27648356PMC5004070W2537817804What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.